Drug

Bendamustine Hydrochloride

In clinical development

Emerging researchLate-stage development

Also known as Belrapzo, Bendamustine, Bendeka, Treanda+2 more

Belrapzo, Bendamustine, Bendeka, Treanda, Vivimusta, bendamustine HCl.

RxNorm1114693 ChEMBLCHEMBL1201734UNII981Y8SX18M

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination With Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients With Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent Non-Hodgkin's Lymphoma

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

A Phase II Study of Brentuximab Vedotin Plus Bendamustine for Relapsed/Refractory Follicular Lymphoma

Clinical trial2026-06-29Results expected Q4 2027 · ClinicalTrials.gov

Phase 2 Study Evaluating the Safety and Efficacy of Pembrolizumab (KEytruda) in Combination With Bendamustine (TREanda) in Relapsed/Refractory Hodgkin Lymphoma

Clinical trial2026-06-23Results expected Q4 2026 · ClinicalTrials.gov

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma

Clinical trial2026-06-18Results expected Q4 2026 · ClinicalTrials.gov

Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in CAR-T Therapy: a Randomized Trial

Clinical trial2026-05-18Results expected Q1 2029 · ClinicalTrials.gov

A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Clinical trial2026-05-04Results posted · ClinicalTrials.gov

Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis

Clinical trial2026-01-01Withdrawn · ClinicalTrials.gov

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Clinical trial2025-12-31Primary completion · ClinicalTrials.gov

A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma

Clinical trial2025-11-24Results posted · ClinicalTrials.gov

Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative Neoplasms

Clinical trial2025-10-06Results expected Q3 2026 · ClinicalTrials.gov

Phase II Study of Bendamustine, Bortezomib, and Dexamethasone (BBD) for Newly Diagnosed Patients With Multiple Myeloma

Clinical trial2025-04-30Results posted · ClinicalTrials.gov

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Research2014-03-03Blood

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Bendamustine Hydrochloride

Aliases & brands

BelrapzoBendamustineBendekaTreandaVivimustabendamustine HCl

RxNorm CUI

1114693

ChEMBL ID

CHEMBL1201734

UNII

981Y8SX18M

Clinical trials

49 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2025

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 49

Phase 18Phase 1 / 211Phase 225Phase 35

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Active, not recruitingPH IIINational Cancer Institute (NCI)n=5472026

Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CompletedPH IIIJanssen Research & Development, LLCn=5782019

An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment

CompletedPH IIITeva Branded Pharmaceutical Products R&D, Inc.n=1022017

Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients

Unknown statusPH IIIShandong Lanjin Pharmaceuticals Co.,Ltdn=962013

A Multi-Center Phase III Study to Investigate the Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

CompletedPH IIICephalonn=1032009

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma

CompletedPH IINational Cancer Institute (NCI)n=1352025

Graft-versus-host Disease Prophylaxis With Combination of Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy)

CompletedPH IISt. Petersburg State Pavlov Medical Universityn=502024

Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)

CompletedPH IISt. Petersburg State Pavlov Medical Universityn=502024

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

CompletedPH I/IIM.D. Anderson Cancer Centern=272023

Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma

CompletedPH IWake Forest University Health Sciencesn=162022

A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients ≤ 65 Years of Age With Previously Untreated Mantle Cell Lymphoma

CompletedPH IISWOG Cancer Research Networkn=532021

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Blood · 2014 · 486 cites

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Cyclophosphamide

Studied across 8 of the same disease areas as Bendamustine Hydrochloride in the shared literature.

8 shared diseases1 shared paper

Doxorubicin

Studied across 8 of the same disease areas as Bendamustine Hydrochloride in the shared literature.

8 shared diseases1 shared paper

Prednisone

Studied across 8 of the same disease areas as Bendamustine Hydrochloride in the shared literature.

8 shared diseases1 shared paper

Vincristine

Studied across 8 of the same disease areas as Bendamustine Hydrochloride in the shared literature.

8 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials